

EMA/149542/2022

## European Medicines Agency decision P/0118/2022

of 13 April 2022

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for rozanolixizumab (EMEA-002681-PIP02-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

### **Disclaimer**

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**

# European Medicines Agency decision

P/0118/2022

of 13 April 2022

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for rozanolixizumab (EMA-002681-PIP02-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by UCB Pharma S.A on 2 June 2021 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 25 February 2022, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1, as amended.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

**Article 1**

A paediatric investigation plan for rozanolixizumab, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

**Article 2**

A deferral for rozanolixizumab, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 3**

A waiver for rozanolixizumab, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 4**

This decision is addressed to UCB Pharma S.A, 60 Allée de la Recherche, 1070 – Brussels, Belgium.

EMA/PDCO/697946/2021  
Amsterdam, 25 February 2022

## Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-002681-PIP02-21

### Scope of the application

**Active substance(s):**

Rozanolixizumab

**Condition(s):**

Treatment of immune thrombocytopenia

**Pharmaceutical form(s):**

Solution for injection

**Route(s) of administration:**

Subcutaneous use

**Name/corporate name of the PIP applicant:**

UCB Pharma S.A

### Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, UCB Pharma S.A submitted for agreement to the European Medicines Agency on 2 June 2021 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 12 July 2021.

Supplementary information was provided by the applicant on 19 November 2021. The applicant proposed modifications to the paediatric investigation plan.

## Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

## **Annex I**

**The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)**

# 1. Waiver

## 1.1. Condition:

Treatment of immune thrombocytopenia

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- solution for injection, subcutaneous use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

# 2. Paediatric investigation plan

## 2.1. Condition:

Treatment of immune thrombocytopenia

### 2.1.1. Indication(s) targeted by the PIP

Treatment of patients with persistent or chronic primary immune thrombocytopenia (ITP) who have had an insufficient response to previous treatments

### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

### 2.1.3. Pharmaceutical form(s)

Solution for injection

### 2.1.4. Measures

| Area                                            | Description                                                                                                                                                                                                                                |
|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Quality-related studies                         | Not applicable                                                                                                                                                                                                                             |
| Non-clinical studies                            | Not applicable                                                                                                                                                                                                                             |
| Clinical studies                                | <b>Study 1 (TP0005)</b><br>Open-label, single arm, safety, tolerability, pharmacokinetic and activity study of rozanolixizumab in paediatric patients from 2 years to less than 18 years of age with primary immune thrombocytopenia (ITP) |
| Extrapolation, modelling and simulation studies | <b>Study 2</b><br>Development of an exposure response, population pharmacokinetic (PK)/pharmacodynamic (PD) model(s) to support the dose selection of rozanolixizumab for Study 1 and confirmation of final paediatric                     |

|                |                  |
|----------------|------------------|
|                | recommended dose |
| Other studies  | Not applicable   |
| Other measures | Not applicable   |

### 3. Follow-up, completion and deferral of PIP

|                                                                                       |               |
|---------------------------------------------------------------------------------------|---------------|
| Concerns on potential long term safety/efficacy issues in relation to paediatric use: | Yes           |
| Date of completion of the paediatric investigation plan:                              | By April 2028 |
| Deferral for one or more measures contained in the paediatric investigation plan:     | Yes           |